Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.

Yoshi Itoh Dupuytren's award
Yoshi Itoh (r) receives the International Dupuytren award 2022 from Dominic Furniss (l)

Yoshi's paper: “A common SNP risk variant MT1-MMP causative for Dupuytren’s disease has a specific defect in collagenolytic activity”, published in Matrix Biology was recognised as the best paper published on the subject of Dupuytren's Disease in the previous year.

On receiving the award Yoshi said: “It is wonderful that our discovery was recognised by the International Dupuytren Society. I feel very honoured to receive the International Dupuytren's Award 2022. Our study demonstrated that one of the causes of Dupuytren disease is the impaired collagen catabolism caused by the single nucleotide polymorphism at the gene of the crucial cell surface collagenolytic enzyme, MT1-MMP/MMP-14. We hope that our discovery will lead to the development of novel therapeutics for Dupuytren disease in the future.

"Around 30% of the worldwide population or 35% of the European population have the low collagenolytic SNP allele. Therefore, further investigation on the impact of the SNP in different pathophysiological conditions is very important. Finally, I wish to express my appreciation to all the authors of the paper. Without everyones’ contributions, it would have been impossible to complete the paper.”

Professor Dominic Furniss, who presented Yoshi with the award said: “My congratulations go to Yoshi for this recognition of his research by the International Dupuytren Society. This is the sixth year running that a team from NDORMS has won the award, which demonstrates our world leading research in this area.”

The International Dupuytren Award recognises exceptional scientific publications on research or clinical treatment of Dupuytren and/or Ledderhose disease. 

Similar stories

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Dr Alex Clarke wins Emerging Leaders Prize for lupus research

Alex is one of three exceptional lupus researchers that have been announced as winners of the Medical Research Foundation’s sixth Emerging Leaders Prize.

A new research computing platform advances the understanding of key biological processes in disease

To respond to advances in technology and try to answer an increasing range of biological questions, the Kennedy Institute has invested in a high-performance computing facility. We speak to Brian Marsden, Associate Professor of Research Informatics at the Kennedy to find out more.

Kennedy programmes support early career researchers

Since 2013 the Kennedy Institute of Rheumatology has been running a Career Development Programme, a scheme to help early career researchers launch their own independent laboratories, and more recently the Innovator Investigator Programme to bring new technologies to core research themes.

Kennedy researchers awarded funding to improve the understanding of inflammatory bowel diseases

A new £1.5M grant from the Medical Research Council (MRC) to the Powrie Group at the Kennedy Institute will help define different pathotypes of inflammatory bowel diseases that could lead to better and more focused treatments for patients.